Evidence map›Paper›PMID 30523056›Full record

ArticleHaematologica2019

HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.

Yoshinobu Maeda, Tomotaka Ugai, Eisei Kondo, Kazuhiro Ikegame, Makoto Murata, Naoyuki Uchida, Toshihiro Miyamoto, Satoshi Takahashi, Kazuteru Ohashi, Hirohisa Nakamae and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences yosmaeda@md.okayama-u.ac.jp.
Tomotaka UgaiDivision of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya.
Eisei KondoDivision of Hematology, Department of Medicine, Kawasaki Medical School, Okayama.
Kazuhiro IkegameDivision of Hematology, Department of Internal Medicine, Hyogo Medical College.
Makoto MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo.
Toshihiro MiyamotoHematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka.
Satoshi TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo.
Kazuteru OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo.
Hirohisa NakamaeDepartment of Hematology, Osaka City University Hospital.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa.
Tetsuya EtoDepartment of Hematology, Hamanomachi Hospital, Fukuoka.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Hokkaido.
Makoto HirokawaDepartment of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University.
Yoshiko AtsutaDepartment of Healthcare Administration, Nagoya University Graduate School of Medicine.
Yoshinobu KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Tochigi.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan.
HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Second allogeneic hematopoietic stem cell transplantation is a curative treatment option for patients with hematologic malignancies. However, it is unclear whether HLA discrepancy between graft and first donor has an impact on the outcome of second transplantation. We retrospectively analyzed 646 patients receiving second transplantation after an initial HLA mismatched transplantation. With regard to graft-

Indexed as

AdolescentAdultAgedFemaleFollow-Up StudiesGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHistocompatibility TestingHLA AntigensHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesHLA Antigens

Identifiers

PMID30523056
PMCPMC6518881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.